The GLP-1 Multi-System Story Gets Louder

This week, the GLP-1 receptor agonist story took another sharp turn. Six articles landed on our desk, and five of them share a common thread: these drugs are doing far more than suppressing appetite. We're watching them reshape cardiovascular risk profiles in autoimmune patients, raise genuine questions about surgical safety, and — in one remarkable trial — show signs of neuroprotection in multiple sclerosis. The weight loss narrative was always the headline. The real story is what happens below the neck.

If you've been following the tirzepatide-versus-semaglutide debate, two enormous real-world studies dropped this week that should settle it — at least on the numbers. And if you're running any of these peptides on a protocol, the pulmonary safety review we cover is required reading. One finding in particular could change how you time your dosing around elective surgery.

Plus, a departure from the GLP-1 universe: thymosin alpha-1 is making serious moves in cancer immunotherapy. Three new studies explain exactly how it restores immune function after chemotherapy — and why oncologists are starting to pay attention.

Tirzepatide vs Semaglutide: The Real-World Verdict Is In

Two studies. Over 55,000 patients. And a clear winner: tirzepatide outperformed semaglutide on nearly every metric that matters. The first study, published in PNAS Nexus, matched 10,339 pairs of patients on either drug and followed them through real clinical outcomes. The second, in The Lancet, tracked 45,093 patients across a broader population. Both reached the same conclusion: tirzepatide produced greater weight loss, better glycemic control, and more consistent results across BMI categories.

What makes these studies different from the earlier SURMOUNT trials is the population. These aren't hand-picked clinical trial participants — they're real patients with real comorbidities, variable adherence, and the messy reality of actual medical care. The fact that tirzepatide's advantage held up in that context is significant. It suggests the dual GIP/GLP-1 mechanism isn't just additive on paper; it translates to meaningful clinical differences at scale. If you're currently on semaglutide and not seeing the results you expected, this data is worth discussing with your prescriber.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

Dulaglutide and Multiple Sclerosis: A Neuroprotection Signal

A randomized trial published this week is the first human evidence that GLP-1 receptor agonists may protect the brain independent of weight loss. Researchers gave dulaglutide to patients with multiple sclerosis and measured functional outcomes. The results: improved walking speed and better manual dexterity. Not marginal gains — clinically meaningful improvements in a disease where those metrics directly track disability progression.

The mechanism isn't fully mapped yet, but preclinical work points to GLP-1 receptor activation reducing neuroinflammation and promoting oligodendrocyte survival — the cells that maintain myelin sheaths. In MS, myelin destruction is the core pathology. If dulaglutide is genuinely slowing that process, it opens a therapeutic avenue that current MS drugs don't address. The trial was small, and we need larger confirmatory studies, but the signal is strong enough that neurologists are paying attention. For anyone running semaglutide or tirzepatide for metabolic reasons, the neuroprotective angle is an intriguing bonus — though it's far too early to dose for that purpose.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

GLP-1 Drugs and Your Lungs: The Safety Map

A systematic review of 19 studies just compiled what we know about GLP-1 receptor agonists and respiratory function. The headline: for most users, the news is reassuring. Semaglutide, tirzepatide, exenatide, and liraglutide did not show meaningful increases in chronic pulmonary disease, asthma exacerbation, or long-term lung function decline. The drugs appear lung-neutral for everyday use.

But there's one critical exception that changes the calculus for anyone on these medications: aspiration risk during anesthesia. GLP-1 agonists slow gastric emptying — that's part of how they work. Under general anesthesia, residual stomach contents dramatically increase the risk of aspiration pneumonia, a potentially fatal complication. The review flagged this as a consistent finding across multiple studies. The practical implication: if you're scheduled for any procedure requiring sedation, your anesthesiologist needs to know you're on a GLP-1 drug, and you may need to pause dosing beforehand. Current guidelines vary, but 1-2 weeks off the medication before surgery is increasingly recommended. This isn't theoretical — it's the kind of safety signal that changes clinical practice.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

Semaglutide's Cardiovascular Edge in Rheumatoid Arthritis

People with rheumatoid arthritis carry roughly double the cardiovascular risk of the general population. Chronic systemic inflammation accelerates atherosclerosis, and the disease itself is an independent risk factor for heart failure. A June 2026 study tested whether semaglutide could interrupt this cycle in obese adults with both type 2 diabetes and RA. The results were striking: a 25% reduction in major adverse cardiovascular events and a 31% drop in heart failure hospitalizations.

The surprise wasn't the cardiovascular benefit — we already knew semaglutide reduced MACE from SELECT and other trials. It was the secondary finding: fewer patients on semaglutide needed escalation to stronger RA medications. The anti-inflammatory properties of GLP-1 receptor activation appear to be doing double duty here, dampening the inflammatory cascade that drives both joint destruction and vascular damage. For anyone managing RA alongside metabolic issues, this study suggests semaglutide might address both conditions simultaneously. That's a meaningful simplification of a complex treatment regimen.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

Do GLP-1 Drugs Sabotage Fat Grafts?

This one matters for anyone considering cosmetic surgery while on GLP-1 therapy. New data shows a 45% complication rate in cosmetic procedures involving fat grafting among semaglutide users. The issue is biological: GLP-1 agonists fundamentally change fat cell behavior. They promote lipolysis, alter adipocyte signaling, and reduce the viability of transferred fat tissue. When a surgeon harvests fat from one area and injects it into another — for facial volume, Brazilian butt lifts, or breast reconstruction — that graft needs to establish blood supply and survive. Semaglutide appears to undermine that survival.

The practical takeaway is straightforward: if you're planning any procedure involving fat grafting, your surgeon will likely recommend pausing GLP-1 therapy for several weeks beforehand. The drugs affect not just the graft itself but also delayed gastric emptying (as discussed in the pulmonary review) and potentially wound healing. This isn't a reason to stop your medication permanently — it's a scheduling consideration. The surgeons reporting these findings are adapting their protocols rather than discouraging GLP-1 use entirely. But it's a complication that didn't exist in the pre-GLP-1 era of cosmetic surgery, and it's catching some patients off guard.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

Thymosin Alpha-1: Restoring Immunity After Chemotherapy

Stepping outside the GLP-1 universe, three 2026 studies converged on a compelling story about thymosin alpha-1 (Tα1) and cancer immunotherapy. Chemotherapy devastates the immune system — it's the trade-off that makes the treatment work. T-cells get exhausted, thymic output drops, and the body's ability to mount an antitumor response craters. Tα1 appears to reverse several of these deficits simultaneously.

The new data shows Tα1 restoring antitumor immunity through three distinct mechanisms: it reactivates exhausted T-cells, boosts thymic regeneration (the organ that produces new T-cells), and enhances the efficacy of checkpoint inhibitor therapy when used in combination. The synergy with checkpoint inhibitors like pembrolizumab is particularly exciting — checkpoint inhibitors work by releasing the brakes on T-cells, but they can only work if functional T-cells exist to unleash. Tα1 may be replenishing the very cells that checkpoint inhibitors need to function. For anyone running a protocol that includes immune-modulating peptides, this research provides the mechanistic detail behind why Tα1 has been gaining traction in longevity and immune optimization circles.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

What to Watch

Next week, we're tracking a new phase 2 trial combining tirzepatide with SGLT2 inhibitors — the first real test of dual-pathway metabolic therapy. We're also expecting updated guidelines from the American Society of Anesthesiologists on GLP-1 perioperative management, which could formalize the aspiration risk protocols we covered this week. And keep an eye on the thymosin alpha-1 space: if the checkpoint inhibitor synergy data holds in larger trials, Tα1 could move from the longevity fringe to mainstream oncology within 18 months.

This Week's BioStack Insight

You just read about semaglutide, tirzepatide, dulaglutide, and thymosin alpha-1 — four compounds with overlapping but distinct mechanisms. Semaglutide showed cardiovascular protection in RA patients and raised surgical safety questions. Tirzepatide won the head-to-head weight loss battle. Dulaglutide signaled neuroprotection. Thymosin alpha-1 is rebuilding immune function after chemotherapy. The BioStack Generator lets you model exactly how these interactions play out against your specific goals and dosing schedule. Whether you're stacking a GLP-1 agonist with immune-modulating peptides, or timing your dosing around a planned procedure, the tool maps the pharmacokinetic overlaps and flags potential conflicts. Takes 2 minutes.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop